Pharma BD Deal Intelligence
Lannett to buy Kremers Urban for $1.23 billion, but the deal carries overhang: the FDA downgraded KU's generic Concerta from AB to BX, with contingent payments…
Kremers Urban is a specialty generic company focused on difficult-to-formulate products and specialized delivery technologies, with 11 applications pending at…
CEO Arthur Bedrosian: 'We are pleased to complete this transformational transaction that further establishes Lannett as a premier specialty pharmaceutical…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Lannett acquired UCB's US specialty generics business Kremers Urban for approximately $1.23B in cash plus contingent payments, expanding into specialty generics including methylphenidate ER for ADHD. Closed November 27, 2015.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Lannett Company, Inc. / UCB S.A. (Kremers Urban Pharmaceuticals Inc.) (this deal) | 2015 | $1.2B | 30 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Biogen Idec Inc. / Elan Corporation plc (Tysabri rights) | 2013 | $3.2B | 77 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
← Browse all deals · How we score deals
More: 2015 deals · Gastroenterology deals